8月20日，振德医疗今日收盘24.6元，上涨1.74%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到18.06倍，创215天以来新低，总市值65.55亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均59.32倍，行业中值39.97倍，振德医疗排 名第38位。 股东方面，截至2025年3月31日，振德医疗股东户数24690户，较上次增加1808户，户均持股市值35.28 万元，户均持股数量2.76万股。 最新一期业绩显示，2025年一季报，公司实现营业收入9.92亿元，同比2.87%；净利润5124.19万元，同 比-30.19%，销售毛利率34.28%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)7振德医疗18.0617.021.1565.55亿行业平均 59.3254.705.08121.09亿行业中值39.9739.752.9659.06亿1九安医疗11.6111.740.91195.93亿2英科医疗 15.3516.551.37242.47亿3山东药玻16.3716.421.88154.82亿4新华医疗16.4015.201.34105.14亿5奥美医疗 17. ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhendermedical, which closed at 23.68 yuan with a PE ratio of 17.38, marking a new low in 165 days, and a total market capitalization of 6.31 billion yuan [1][2] - The average PE ratio for the medical device industry is 56.58, with a median of 39.97, positioning Zhendermedical at 37th place within the industry [1][2] - As of March 31, 2025, Zhendermedical has 24,690 shareholders, an increase of 1,808 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Zhendermedical specializes in the research, production, and sales of medical and health products, with key offerings in basic care, surgical infection control, pressure treatment, stoma care, and modern wound care [1] - The latest quarterly report for Q1 2025 shows Zhendermedical achieved a revenue of 999.2 million yuan, a year-on-year increase of 2.87%, while net profit was 51.24 million yuan, reflecting a year-on-year decrease of 30.19%, with a gross margin of 34.28% [1]

截至2025年一季报，共有3家机构持仓振德医疗，其中基金3家，合计持股数145.13万股，持股市值0.31 亿元。 8月14日，振德医疗今日收盘23.22元，下跌1.32%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到17.04倍，总市值61.87亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.76倍，行业中值39.14倍，振德医疗排 名第36位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5振德医疗17.0416.061.0861.87亿行业平均 55.7651.784.91117.92亿行业中值39.1439.592.8556.79亿1九安医疗11.1811.310.88188.72亿2英科医疗 14.7815.931.32233.49亿3山东药玻16.1716.211.86152.90亿4新华医疗16.3115.111.33104.53亿6奥美医疗 17.0716.731.7561.68亿7九强生物17.6516.412.1687.42亿8康德莱18.2218.241.5139.27亿9奥泰生物 18.4419.441.4958.81亿10维力医疗18.4 ...

最新一期业绩显示，2025年一季报，公司实现营业收入9.92亿元，同比2.87%；净利润5124.19万元，同 比-30.19%，销售毛利率34.28%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5振德医疗17.3716.371.1063.04亿行业平均 57.5153.344.97120.28亿行业中值41.2539.962.9558.75亿1九安医疗11.2611.380.89189.95亿2英科医疗 15.0516.231.34237.81亿3山东药玻16.1716.221.86152.96亿4新华医疗16.9415.701.38108.60亿6奥美医疗 17.5417.191.8063.39亿7九强生物17.9216.672.2088.77亿8康德莱18.7518.761.5540.40亿9维力医疗 18.7920.082.3644.05亿10奥泰生物19.3120.361.5661.58亿11鱼跃医疗20.2319.842.73358.29亿12安图生物 21.1920.232.72241.60亿 8月12日，振德医疗今日收盘23.66元，上涨3.59%，滚动市盈率PE（当前股价与前四 ...

8月11日，振德医疗今日收盘22.84元，上涨2.79%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到16.76倍，创158天以来新低，总市值60.86亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均56.56倍，行业中值39.76倍，振德医疗排 名第35位。 截至2025年一季报，共有3家机构持仓振德医疗，其中基金3家，合计持股数145.13万股，持股市值0.31 亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入9.92亿元，同比2.87%；净利润5124.19万元，同 比-30.19%，销售毛利率34.28%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)4振德医疗16.7615.801.0760.86亿行业平均 56.5652.664.92118.97亿行业中值39.7639.192.9457.67亿1九安医疗11.2811.400.89190.28亿2英科医疗 15.1416.331.35239.25亿3山东药玻16.1616.211.86152.83亿5新华医疗17.1715.911.40110.05亿6奥美医疗 17.1816.831.7762. ...

Core Viewpoint - The stock of Zhendemedical (603301) has shown a decline in price and mixed capital flow, indicating potential volatility in the market [1][2]. Financial Performance - As of August 6, 2025, Zhendemedical's stock closed at 22.08 yuan, down 1.3% with a trading volume of 27,700 hands and a transaction amount of 61.39 million yuan [1]. - The company reported a main revenue of 992 million yuan for Q1 2025, a year-on-year increase of 2.87%, while the net profit attributable to shareholders was 51.24 million yuan, a decrease of 30.19% year-on-year [4]. - The company's gross profit margin stands at 34.28%, which is significantly lower than the industry average of 51.31% [4]. Capital Flow Analysis - On August 6, 2025, the net outflow of main funds was 5.89 million yuan, accounting for 9.6% of the total transaction amount, while retail investors saw a net inflow of 7.72 million yuan, representing 12.57% of the total [1]. - Over the past five days, the financing balance has increased, with a net financing purchase of 2.25 million yuan on August 6, 2025, contributing to a cumulative net purchase of 14.04 million yuan over three days [2]. Industry Comparison - Zhendemedical's total market value is 5.883 billion yuan, which is below the industry average of 11.525 billion yuan, ranking 59th out of 123 companies in the medical device sector [4]. - The company's price-to-earnings ratio (P/E) is 28.7, significantly lower than the industry average of 61.65, indicating a potentially undervalued stock [4]. Institutional Ratings - In the last 90 days, two institutions have rated Zhendemedical with a "buy" recommendation, and the average target price set by institutions is 27.13 yuan [5].

振德医疗用品股份有限公司的主营业务是医疗和健康产品的研发、生产与销售。公司的主要产品是基础 护理、手术感控、压力治疗与固定、造口及现代伤口护理、感控防护。公司曾先后获得包括省级重点企 业研究院、省级工程技术研究中心、省级高新技术企业研究中心、省级企业技术中心、省创新型试点企 业、省级专利示范企业在内的多项技术奖项，并通过国家高新技术企业评审。 8月4日，振德医疗今日收盘22.42元，上涨1.04%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到16.46倍，创145天以来新低，总市值59.74亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.32倍，行业中值38.11倍，振德医疗排 名第36位。 截至2025年一季报，共有3家机构持仓振德医疗，其中基金3家，合计持股数145.13万股，持股市值0.31 亿元。 来源：金融界 最新一期业绩显示，2025年一季报，公司实现营业收入9.92亿元，同比2.87%；净利润5124.19万元，同 比-30.19%，销售毛利率34.28%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5振德医疗16.4615.511.0559.74 ...

Core Viewpoint - Zhendermedical's stock closed at 21.87 yuan, up 2.53%, with a rolling PE ratio of 16.05, marking a new low in 75 days, and a total market value of 5.827 billion yuan [1] Company Summary - Zhendermedical specializes in the research, production, and sales of medical and health products, focusing on basic care, surgical infection control, pressure treatment and fixation, stoma and modern wound care, and infection control protection [1] - The company has received multiple technical awards, including provincial key enterprise research institutes and high-tech enterprise certifications, and has passed the national high-tech enterprise review [1] - For Q1 2025, Zhendermedical reported revenue of 999.2 million yuan, a year-on-year increase of 2.87%, and a net profit of 51.2419 million yuan, a year-on-year decrease of 30.19%, with a gross profit margin of 34.28% [1] Industry Summary - The average PE ratio for the medical device industry is 53.52, with a median of 37.14, placing Zhendermedical at 36th in the industry ranking [2] - The industry average and median PE ratios indicate a higher valuation compared to Zhendermedical's current PE ratio of 16.05 [2] - The total market value of Zhendermedical is 5.827 billion yuan, which is significantly lower than the industry average market value of 111.58 billion yuan [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Zhendermedical, indicating a decline in net profit despite a slight increase in revenue [1][2] - Zhendermedical's closing stock price is 20.86 yuan, with a rolling PE ratio of 15.31 times, which is significantly lower than the industry average of 49.70 times [1][2] - The company has a total market capitalization of 5.558 billion yuan, ranking 36th in the medical device industry based on PE ratio [1][2] Group 2 - As of the first quarter of 2025, 15 institutions hold shares in Zhendermedical, with a total holding of 154.3014 million shares valued at 3.331 billion yuan [1] - The main business of Zhendermedical includes the research, production, and sales of medical and health products, with key products in basic care, surgical infection control, pressure treatment, and modern wound care [1] - The latest financial report shows that for the first quarter of 2025, the company achieved an operating income of 999.2 million yuan, a year-on-year increase of 2.87%, while net profit was 51.2419 million yuan, a year-on-year decrease of 30.19% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhend Medical, which closed at 20.55 yuan with a PE ratio of 15.08, marking a 15-day low, and a total market capitalization of 5.476 billion yuan [1][2] - Zhend Medical ranks 34th in the medical device industry, which has an average PE ratio of 49.51 and a median of 36.17 [1][2] - As of the first quarter of 2025, 15 institutions hold shares in Zhend Medical, with a total holding of 154.3014 million shares valued at 3.331 billion yuan [1] Group 2 - The main business of Zhend Medical includes the research, production, and sales of medical and health products, focusing on basic care, surgical infection control, pressure treatment, stoma care, and modern wound care [1] - The latest financial results for the first quarter of 2025 show Zhend Medical achieved a revenue of 999.2 million yuan, a year-on-year increase of 2.87%, while net profit was 51.2419 million yuan, reflecting a year-on-year decrease of 30.19%, with a gross profit margin of 34.28% [1]